

DRUG PRIOR AUTHORIZATION COMMITTEE

June 21, 2018

Agenda

Department of Natural Resources
1101 Riverside Dr., Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Mitch Ruth
10:25 - 10:35	DUR Update	Mark Roaseau

Old Business

10:35 – 10:40	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Mark Roaseau
---------------	--	--------------

New Business

10:40 – 11:00	B. Proposed Actions - New Drug/Product Review (See website and Attached Summary)	Mark Roaseau
---------------	--	--------------

- i. Open Access**
- ii. Clinical Edit/Step Therapy**
- iii. PDL Products**
- iv. Prior Authorization**
 - Discussion
 - Public Hearing
 - Decision

11:00 – 11:45	<u>C. Clinical Edits</u>	
I.	Luxturna Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
II.	Mepsevii Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
III.	Symdeko Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
IV.	Yescarta Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	

11:45 – 1:00	<u>D. Preferred Drug List (PDL)</u>	
I.	Amylin Analogs <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
II.	Antihyperuricemic Agents	

- Discussion
 - Public Hearing
 - Decision
- III. Bile Salts Agents**
- Discussion
 - Public Hearing
 - Decision
- IV. Bone Deossification Suppression Agents (including Calcitonin)**
- Discussion
 - Public Hearing
 - Decision
- V. BPH Agents (formerly Androgen Hormone Inhibitors)**
- Discussion
 - Public Hearing
 - Decision
- VI. Cephalosporins and Related Antibiotics - Oral**
- Discussion
 - Public Hearing
 - Decision
- VII. Cryopyrin-Associated Periodic Syndrome (CAPS) Agents**
- Discussion
 - Public Hearing
 - Decision
- VIII. DPP-IV (Dipeptidyl Peptidase-4) Inhibitors**
- Discussion
 - Public Hearing
 - Decision
- IX. Electrolyte Depleters (Phosphate Binders)**
- Discussion
 - Public Hearing
 - Decision
- X. Fluoroquinolones – Oral**
- Discussion
 - Public Hearing
 - Decision
- XI. GI Antibiotics – Oral:**
- Discussion
 - Public Hearing
 - Decision
- XII. GLP-1 Receptor Agonists (Anti-Diabetic Mimetics)**
- Discussion
 - Public Hearing
 - Decision
- XIII. Growth Hormones and Growth Factors**
- Discussion
 - Public Hearing
 - Decision
- XIV. Hematopoietic Agents**
- Discussion
 - Public Hearing
 - Decision
- XV. Hepatitis C Therapy**
- Discussion
 - Public Hearing
 - Decision

- XVI. Insulins**
 - Discussion
 - Public Hearing
 - Decision
- XVII. Insulins – Long Acting**
 - Discussion
 - Public Hearing
 - Decision
- XVIII. Insulins – Mix**
 - Discussion
 - Public Hearing
 - Decision
- XIX. Insulins – Rapid Acting**
 - Discussion
 - Public Hearing
 - Decision
- XX. Intravaginal Antibiotics**
 - Discussion
 - Public Hearing
 - Decision
- XXI. Macrolides – Adult**
 - Discussion
 - Public Hearing
 - Decision
- XXII. Macrolides – Pediatric**
 - Discussion
 - Public Hearing
 - Decision
- XXIII. Methotrexate Products – Oral and Injectable**
 - Discussion
 - Public Hearing
 - Decision
- XXIV. Multiple Sclerosis (MS) Agents**
 - Discussion
 - Public Hearing
 - Decision
- XXV. Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- XXVI. Oral Anti-Diabetics: Biguanides**
 - Discussion
 - Public Hearing
 - Decision
- XXVII. Oral Anti-Diabetics: Combinations**
 - Discussion
 - Public Hearing
 - Decision
- XXVIII. Oral Anti-Diabetics: Meglitinides**
 - Discussion
 - Public Hearing
 - Decision
- XXIX. Oral Anti-Diabetics: Sulfonylureas 2nd Generation**
 - Discussion
 - Public Hearing
 - Decision

- XXX. **Oral Anti-Diabetics: Thiazolidinediones**
 - Discussion
 - Public Hearing
 - Decision
- XXXI. **Penicillins**
 - Discussion
 - Public Hearing
 - Decision
- XXXII. **Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- XXXIII. **Targeted Immune Modulators (formerly Biologics – Disease Modifying Anti-Rheumatic Drugs- DMARDs)**
 - Discussion
 - Public Hearing
 - Decision
- XXXIV. **Tetracyclines**
 - Discussion
 - Public Hearing
 - Decision
- XXXV. **Urinary Tract Antispasmodics**
 - Discussion
 - Public Hearing
 - Decision
- XXXVI. **Antipsychotics - 2nd Generation (Atypical)**
 - Discussion
 - Public Hearing
 - Decision
- XXXVII. **ADHD Therapy**
 - Discussion
 - Public Hearing
 - Decision

E. Preferred Drug List Classes for Sept/Oct

- i. Process Discussion
- ii. Therapeutic classes/to be announced at the meeting

1:00

LUNCH

1:15-1:30

Program Utilization Information-Xerox Update

Luke Boehmer

1:30-1:50

Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: September 20, 2018
Missouri Coalition for Community Behavioral Healthcare
Lower Level CEO Room, 221 Metro Drive, Jefferson City, MO